FLT 190 / Spur Therapeutics - LARVOL DELTA

Dual Impact: Assessing How Conventional Anticancer Drugs Affect Both Ovarian Cancer Cells and Tumor-Associated Bacteria (ASM Microbe 2025) - "Carboplatin and paclitaxel (3.125–200 μM) and doxorubicin (0.781–50 μM) were tested on ovarian cancer cell lines (SKOV3, Ovcar3, Kuramochi) and a normal cell line (FT190) to assess their cytotoxicity, using six 1:5 serial dilutions...Minimum Inhibitory Concentrations (MICs) for standard antibiotics (ampicillin, tetracycline, gentamicin, vancomycin) were also determined for each bacterial strain...These findings suggest that while anticancer drugs effectively target ovarian cancer cells, they do not significantly affect some tumor-associated bacteria, which may possess resistance mechanisms and influence cancer progression. Further research is needed to explore the combination of anticancer drugs with tumor-associated microbiota to enhance chemotherapy efficacy."

Infectious Disease • Oncology • Ovarian Cancer • Pneumococcal Infections • Pneumonia • Solid Tumor

The G-Protein-Coupled Estrogen Receptor Selective Agonist G-1 Attenuates Cell Viability and Migration in High-Grade Serous Ovarian Cancer Cell Lines. (PubMed, Int J Mol Sci) - "This study was conducted to evaluate the relationship of GPER, ovarian cancer subtypes, i.e., high-grade serous cell lines (OV90 and OVCAR420), as well as the cell type that is the potential origin of HGSC ovarian cancer (i.e., the fallopian tube cell line FT190)...Strikingly, attenuated cell proliferation and migration behaviors were observed in the presence of G-1. Thus, our in vitro study reveals the impact of the origin of HGSC ovarian cancers and highlights the GPER agonist G-1 as a potential therapy for ovarian cancer."

Journal • Preclinical • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

Form 424B4 Freeline Therapeutics (Streetinsider.com) - Preclinical results from the 13-week GLP-compliant toxicology studies showed that administration of FLT190 was effective in producing significantly increased GLA activity...In July 2019, we began recruiting patients for our MARVEL-1 clinical trial, which is a Phase 1/2 dose-finding clinical trial to evaluate the safety and efficacy of FLT190 for the treatment of Fabry disease, with our first patient dosed in August 2019....But continue to recruit patients for our ECLIPSE study, through which we screen patients for eligibility and possible participation in our Phase 1/2 dose-finding clinical trial....We are developing FLT201 for the treatment of type 1 Gaucher disease...We are the only company to date that has announced a program for the development of an AAV gene therapy for the treatment of type 1 Gaucher disease. We plan to file the IND and initiate the Phase 1/2 clinical trial for this program in 2021."

New P1/2 trial • Preclinical • Trial status • Fabry Disease • Gaucher Disease • Genetic Disorders

IPO Launch: Freeline Therapeutics Proposes $125 Million IPO (The Street) - "According to an amended registration statement, Freeline Therapeutics (FRLN) intends to raise $125 million from the selling of ADSs that represent underlying common stock at an IPO. The company is developing a pipeline of candidates for the treatment of hemophilia, Gaucher disease, and Fabry disease....FRLN seeks an above-average size of IPO transaction to advance its hemophilia, Gaucher disease and Fabry disease care pipeline."

Financing • Fabry Disease • Gaucher Disease • Genetic Disorders • Hemophilia

Freeline Therapeutics and Checkmate Pharma Make Opening IPO Moves (Xconomy) - "The biotech IPO queue has added two more companies. Freeline Therapeutics and Checkmate Pharmaceuticals have each filed the regulatory paperwork to offer shares to the public....Freeline says in its prospectus that it expects to report additional data from the FLT180a study in the second half of this year. The company plans to advance the gene therapy to a pivotal study in 2021. The other programs in its pipeline include FLT190, a gene therapy for the rare enzyme deficiency Fabry disease that is in Phase 1/2 testing. Two other programs, FLT201 for Gaucher disease, another rare disorder caused by an enzyme deficiency, and FLT210 for hemophilia A, are in preclinical development."

Financing • Fabry Disease • Gaucher Disease • Genetic Disorders • Hemophilia • Type 1 Gaucher Disease

Freeline Raises $120 Million to Advance Gene Therapy Programs (Pharmalive) - "Freeline...announced the closing of a $120 million extended Series C financing. This was on top of Syncona’s previously announced Series C investment in Freeline of $40 million, with another $80 million in new capital....The company plans to use the monies raised to advance its lead program in Hemophilia B into a pivotal trial. It also will continue its Phase I/II clinical program for Fabry Disease and advance its pipeline for Gaucher Disease and Hemophilia A."

Financing • Fabry Disease • Gaucher Disease • Genetic Disorders • Hemophilia